Evofem Biosciences, Inc.
Every calculator, already run for EVFM
Open the full toolkit →You have the numbers on EVFM. Get the argument.
A written report on which of these readings actually decide the outcome for Evofem Biosciences, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Ownership & short interest
Insider Trading Activity for EVFM
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Evofem Biosciences, Inc.
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
EVFM — frequently asked
Is EVFM a buy right now?
Wall Street's consensus rating on Evofem Biosciences, Inc. is none. Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is EVFM overvalued?
EVFM trades at — trailing earnings, against a DCF fair value of $2 per share. The current price implies -10% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
Compare Evofem Biosciences, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Evofem Biosciences, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full EVFM research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Evofem Biosciences, Inc., in minutes. 3 free reports included with every account — no credit card required.